BG-9928 Biogen Idec

Current Opinion in Investigational Drugs

Volumn 6, Issue 9, 2005, Pages 962-968

  Doggrell, Sheila A ^a  

^a AUCKLAND UNIVERSITY OF TECHNOLOGY   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 DIPROPYL 8 (4 SULFOPHENYL)XANTHINE; 2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 3 [4 (2,3,6,7 TETRAHYDRO 2,6 DIOXO 1,3 DIPROPYL 1H PURIN 8 YL)BICYCLO[2.2.2]OCTAN 1 YL]PROPIONIC ACID; 6 N (2 HYDROXYCYCLOPENTYL)ADENOSINE; 8 (2 NOR 1 ADAMANTYL) 1,3 DIPROPYLXANTHINE; 8 [4 (2 AMINOETHYLCARBAMOYL)METHOXYPHENYL] 1,3 DIPROPYLXANTHINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; BAMIFYLLINE; BIO 4683; BIO 5770; BIO 7505; BIO 8170; BIO 9002; DIURETIC AGENT; FUROSEMIDE; MRE 2029F20; N (4 CYANOPHENYL) 2 [4 (2,3,6,7 TETRAHYDRO 2,6 DIOXO 1,3 DIPROPYL 1H PURIN 8 YL)PHENOXY]ACETAMIDE; NAXIFYLLINE; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIURESIS; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HEART PROTECTION; HUMAN; LICENSING; NATRIURESIS; NONHUMAN; PATENT; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION;

ANIMALS; CLINICAL TRIALS; DIURETICS; HEART FAILURE, CONGESTIVE; HUMANS; RECEPTOR, ADENOSINE A1; STRUCTURE-ACTIVITY RELATIONSHIP; XANTHINES;

EID: 24644431990     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. 237166 Biogen and CV Therapeutics announce collaboration on CVT-124 for congestive heart failure. CV Therapeutics Inc PRESS RELEASE 1997 March 10
2. 1-adenosine antagonist 1,3-dipropyl-8-[2-(5,6-epoxynorbonyl)]-xanthine. Pfister JR, Belardinelli L, Lee G, Lum RT, Milner P, Stanley WC, Linden J, Baker SP, Schreiner G J MED CHEM 1997 40 12 1773-1778
3. 1 receptor mediated myocardial infarct size reduction by endogenous adenosine is exerted primarily during ischaemia. Zhao ZQ, Nakanishi K, McGee DS, Tan P, Vinten-Johansen J CARDIOVASC RES 1994 28 270-279
4. 403633 Broad-spectrum cardioprotection with adenosine. Vinten-Johansin J, Thourani VH, Ronson RS, Jordan JE, Zhao ZQ, Nakamura M, Velez D, Guyton RA ANN THORAC SURG 1999 68 1942-1948
5. 436187 CV Therapeutics Inc. HAMBRECHT & QUIST 2002 January 07-10 116
6. 1-receptor antagonists. Patter RC, Kiesman WF, Conlon PR, Kumaravel G, Ensinger CL, Dowling J, Peng B, Smits G, Jin X, Lutterodt FA, Fu K et al ACS 2002 224 MEDI 417
7. 463222 American Chemical Society - 224th National Meeting (Part XIV), Adenosine Receptor Symposium, Boston, MA, USA, 18-22 August 2002.. Rotella D IDDB MEETING REPORT 2002 August 18-22
8. 512976 Biogen and IDEC Pharmaceuticals complete merger to create now biotechnology industry leader. Biogen Inc PRESS RELEASE 2003 November 12
9. 514063 BG9928, an oral adenosine antagonist, preserves renal function, improves sodium excretion and is well tolerated in heart failure patients. Greenberg BH, Banish D, Goldman S, Thomas I, Havranek E, Bijou R, O'Leary M, Zhu Y, Ticho B, Massie B, Abraham W CIRCULATION 2003 108 17 Abs 1602
10. 579202 Present and future pharmacotherapy for heart failure. Doggreli SA, Brown L EXPERT OPIN PHARMACOTHER 2002 3 71 915-930
11. 580138 Pathophysiology of chronic heart failure. Francis GS AM J MED 2001 110 7A 37S-46S
12. 580141 Our future society: A global challenge. Kelley D CIRCULATION 1997 95 2459-2464
13. 1 adenosine receptor antagonists on infarct size and multiple cycle ischemic preconditioning in anesthetized dogs. Auchampach JA, Jin X, Moore J, Wan TC, Kreckler LM, Ge ZD, Narayanan J, Whalley E, Kiesman W, Ticho B, Smits G, Gross GJ J PHARMACOL EXP THER 2004 308 3 846-856
14. 1 adenosine receptor antagonist, in rats and nonhuman primates Ticho B, Whalley E, Gill A, Lutterodt F, Jin X, Auchampach J, Smits G DRUG DEV RES 2003 58 4 486-492
15. 2b adenosine receptor blockade improves diabetes and attenuates renal and cardiac histopathology in animals with the metabolic syndrome. Tofovic SP, Salah EM, Smits G, Whalley E, Ticho B, Jackson EK J AM COLL CARDIOL 2003 41 Suppl A 193A
16. 1 adenosine antagonist, in rats and healthy human subjects. Ticho B, Marbury T, Zhu Y, Porter K, O'Leary M, Smits G, Letterodt FA, Beckman C DRUG DEV RES 2002 56 4 556
17. 1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Gottlieb SS, Brater DC, Thomas I, Havranek E, Boure R, Goldman S, Dyer F, Gomez M, Bennett D, Ticho B, Beckman E, Abraham WT CIRCULATION 2002 105 11 1348-1353
18. 1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure. Gottlieb SS, Skettino SL, Wolff A, Beckman E, Fisher ML, Freudenberger R, Gladwell T, Marshall J, Cines M, Bennett D, Liittschwager EB J AM COLL CARDIOL 2000 35 1 56-59
19. cp rats chronically treated with salt and furosemide. Jackson EK, Kost CK, Herzer WA, Smits GJ, Tofovic SP J PHARMACOL EXP THER 2001 38 3 618-624
20. 1 receptor agonist GR79236, in an anaesthetized rabbit model of myocardial ischaemia and reperfusion. Sheldrick A, Gray KM, Drew GM, Louttit JB BR J PHARMACOL 1999 128 2 385-395
21. 611151 Pathogenesis and management of sodium and water retention in cardiac failure and cirrhosis. Schrier RW, Gurevich AK, Cadnapaphomchai MA SEMIN NEPHROL 2001 21 2 157-172
22. 611152 Race and renal impairment in heart failure - mortality in blacks versus whites. Smith GL, Shlipak MG, Havranek EP, Masoudi FA, McClellan WM, Foody JM, Rathore SS, Krumholz HM CIRCULATION 2005 111 10 1270-1277
23. 1 receptor antagonists and the kidney. Modlinger PS, Welch WJ CURR OPIN NEPHROL HYPERTENS 2003 12 5 497-502
24. 1 adenosine receptor antagonists block ischemia-reperfusion injury of the heart. Neely CF, DiPierro FV, Kong M, Greelish JP, Gardner TJ CIRCULATION 1996 94 9 Suppl II376-II380
25. 611159 Sustained reduction in myocardial reperfusion injury with an adenosine receptor antagonist: Possible role of the neutrophil chemoattractant response. Forman MB, Vitola JV, Velasco CE, Dubey RK, Jackson EK J PHARMACOL EXP THER 2000 292 3 929-938
26. 2B adenosine receptors. Volpini R, Constanze S, Vittori S, Cristalli G, Klotz KN CURR TOP MED CHEM 2003 3 4 427-443
27. 2B receptors in the regulation of TNF-α production by human monocytes. Zhang JG, Hepburn L, Cruz G, Borman RA, Clark KL BIOCHEM PHARMACOL 2005 69 6 883-889
28. 3H]-MRE 2029F20. Gessi S, Varani K, Merighi S, Cattabriga E, Pancaoldi C, Szabadkai Y, Rizzuto R, Klotz KN, Leung E, MacLennan S, Baraldi PG, Bores PA. MOL PHARMACOL 2005 67 6 2137-2147
29. 611614 Adenosine receptors: G protein-mediated signalling and the role of accessory proteins. Klinger M, Freissmuth M, Nanoff C CELL SIGNAL 2002 14 2 99-108
30. 1 receptor. Li ZM, Tao Y, Porter K, TenHoor CCS DRUG METAB REV 2004 36 Suppl 1 Abs 272
31. 613541 Cardiovascular drugs and serum uric acid. Reves AJ CARDIOVASCULAR DRUGS THER 2003 17 5-6 397-414
32. 613543 Mechanisms and management of diuretic resistance in congestive heart failure. De Bruyne LK POSTGRADUATE MED J 2003 79 931 268-271